X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs STRIDES PHARMA SCIENCE - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD STRIDES PHARMA SCIENCE LUPIN LTD/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 29.7 50.9 58.2% View Chart
P/BV x 2.8 1.1 255.8% View Chart
Dividend Yield % 0.6 0.4 133.6%  

Financials

 LUPIN LTD   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
LUPIN LTD/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,4651,147 127.7%   
Low Rs727642 113.3%   
Sales per share (Unadj.) Rs349.6317.2 110.2%  
Earnings per share (Unadj.) Rs5.67.8 70.8%  
Cash flow per share (Unadj.) Rs29.625.1 118.0%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.50.2 204.0%  
Book value per share (Unadj.) Rs300.3274.3 109.5%  
Shares outstanding (eoy) m452.0889.50 505.1%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.12.8 111.2%   
Avg P/E ratio x197.2114.0 172.9%  
P/CF ratio (eoy) x37.135.7 103.8%  
Price / Book Value ratio x3.63.3 111.9%  
Dividend payout %90.025.5 352.9%   
Avg Mkt Cap Rs m495,50280,058 618.9%   
No. of employees `00017.02.5 679.8%   
Total wages/salary Rs m28,6474,341 660.0%   
Avg. sales/employee Rs Th9,273.611,325.8 81.9%   
Avg. wages/employee Rs Th1,681.01,731.4 97.1%   
Avg. net profit/employee Rs Th147.4280.1 52.6%   
INCOME DATA
Net Sales Rs m158,04228,394 556.6%  
Other income Rs m1,504941 159.8%   
Total revenues Rs m159,54529,334 543.9%   
Gross profit Rs m31,4753,965 793.7%  
Depreciation Rs m10,8591,540 704.9%   
Interest Rs m2,0441,962 104.1%   
Profit before tax Rs m20,0761,403 1,430.8%   
Minority Interest Rs m-710-   
Prior Period Items Rs m35-168 -21.0%   
Extraordinary Inc (Exp) Rs m-14,644-436 3,360.1%   
Tax Rs m2,88597 2,964.6%   
Profit after tax Rs m2,513702 357.9%  
Gross profit margin %19.914.0 142.6%  
Effective tax rate %14.46.9 207.2%   
Net profit margin %1.62.5 64.3%  
BALANCE SHEET DATA
Current assets Rs m122,09524,836 491.6%   
Current liabilities Rs m50,95618,993 268.3%   
Net working cap to sales %45.020.6 218.7%  
Current ratio x2.41.3 183.2%  
Inventory Days Days8571 119.2%  
Debtors Days Days120113 105.7%  
Net fixed assets Rs m129,87634,289 378.8%   
Share capital Rs m904895 101.0%   
"Free" reserves Rs m134,86623,651 570.2%   
Net worth Rs m135,77124,546 553.1%   
Long term debt Rs m64,24515,513 414.1%   
Total assets Rs m263,05465,437 402.0%  
Interest coverage x10.81.7 631.2%   
Debt to equity ratio x0.50.6 74.9%  
Sales to assets ratio x0.60.4 138.5%   
Return on assets %1.74.1 42.5%  
Return on equity %1.92.9 64.7%  
Return on capital %3.76.9 54.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14115,697 338.5%   
Fx outflow Rs m19,335735 2,629.1%   
Net fx Rs m33,80714,962 226.0%   
CASH FLOW
From Operations Rs m17,5121,871 936.1%  
From Investments Rs m-14,0735,826 -241.6%  
From Financial Activity Rs m-14,921-10,157 146.9%  
Net Cashflow Rs m-11,482-2,615 439.1%  

Share Holding

Indian Promoters % 46.6 27.7 168.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 37.8 29.9%  
FIIs % 31.9 8.6 370.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 25.9 39.0%  
Shareholders   98,259 56,241 174.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Nov 19, 2018 01:21 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS